BRIEF-Windtree Announces Positive Phase 2B Topline Clinical Results Of Istaroxime

Reuters09-30

Sept 30 (Reuters) - Windtree Therapeutics Inc :

* WINDTREE ANNOUNCES POSITIVE PHASE 2B TOPLINE CLINICAL RESULTS WITH ISTAROXIME SIGNIFICANTLY IMPROVING CARDIAC FUNCTION AND BLOOD PRESSURE IN HEART FAILURE PATIENTS IN EARLY CARDIOGENIC SHOCK

* WINDTREE THERAPEUTICS INC - ISTAROXIME IMPROVES SYSTOLIC BLOOD PRESSURE, CARDIAC OUTPUT, RENAL FUNCTION

* WINDTREE THERAPEUTICS INC - NYHA HEART FAILURE CLASSIFICATION IMPROVED UP TO 72 HOURS

* WINDTREE THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT IN IMPROVING SYSTOLIC BLOOD PRESSURE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2471380273?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-30 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2471380273","market":"us","top_or_hot":-1,"title":"BRIEF-Windtree Announces Positive Phase 2B Topline Clinical Results Of Istaroxime","media":"Reuters","content":"<html><body><p>Sept 30 (Reuters) - Windtree <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * WINDTREE ANNOUNCES POSITIVE PHASE 2B TOPLINE CLINICAL RESULTS WITH ISTAROXIME SIGNIFICANTLY IMPROVING CARDIAC FUNCTION AND BLOOD PRESSURE IN HEART FAILURE PATIENTS IN EARLY CARDIOGENIC SHOCK</p><p>   * WINDTREE THERAPEUTICS INC - ISTAROXIME IMPROVES SYSTOLIC BLOOD PRESSURE, CARDIAC OUTPUT, RENAL FUNCTION</p><p>   * WINDTREE THERAPEUTICS INC - NYHA HEART FAILURE CLASSIFICATION IMPROVED UP TO 72 HOURS</p><p>   * WINDTREE THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT IN IMPROVING SYSTOLIC BLOOD PRESSURE</p><p>Source text for Eikon:   Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Windtree Announces Positive Phase 2B Topline Clinical Results Of Istaroxime</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Windtree Announces Positive Phase 2B Topline Clinical Results Of Istaroxime\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-30 20:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 30 (Reuters) - Windtree Therapeutics Inc   :   * WINDTREE ANNOUNCES POSITIVE PHASE 2B TOPLINE CLINICAL RESULTS WITH ISTAROXIME SIGNIFICANTLY IMPROVING CARDIAC FUNCTION AND BLOOD PRESSURE IN HEART...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2471380273","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2471380273","pubTimestamp":1727700280,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 30  - Windtree Therapeutics Inc   :   * WINDTREE ANNOUNCES POSITIVE PHASE 2B TOPLINE CLINICAL RESULTS WITH ISTAROXIME SIGNIFICANTLY IMPROVING CARDIAC FUNCTION AND BLOOD PRESSURE IN HEART FAILURE PATIENTS IN EARLY CARDIOGENIC SHOCK   * WINDTREE THERAPEUTICS INC - ISTAROXIME IMPROVES SYSTOLIC BLOOD PRESSURE, CARDIAC OUTPUT, RENAL FUNCTION   * WINDTREE THERAPEUTICS INC - NYHA HEART FAILURE CLASSIFICATION IMPROVED UP TO 72 HOURS   * WINDTREE THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT IN IMPROVING SYSTOLIC BLOOD PRESSURESource text for Eikon:   Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","WINT":"Windtree Therapeutics, Inc."},"translate_title":"BRIEF-Windtree宣布Istaroxime的积极2B期顶线临床结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WINT":0.9},"content_text":"Sept 30 (Reuters) - Windtree Therapeutics Inc   :   * WINDTREE ANNOUNCES POSITIVE PHASE 2B TOPLINE CLINICAL RESULTS WITH ISTAROXIME SIGNIFICANTLY IMPROVING CARDIAC FUNCTION AND BLOOD PRESSURE IN HEART FAILURE PATIENTS IN EARLY CARDIOGENIC SHOCK   * WINDTREE THERAPEUTICS INC - ISTAROXIME IMPROVES SYSTOLIC BLOOD PRESSURE, CARDIAC OUTPUT, RENAL FUNCTION   * WINDTREE THERAPEUTICS INC - NYHA HEART FAILURE CLASSIFICATION IMPROVED UP TO 72 HOURS   * WINDTREE THERAPEUTICS INC - STUDY MEETS PRIMARY ENDPOINT IN IMPROVING SYSTOLIC BLOOD PRESSURESource text for Eikon:   Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2471380273"}